The company that turned a stool sample into a window on your gut - and read it in RNA.
Above: the logomark, with a strand of RNA coiled inside the "g." Yes, the branding is a science pun. They earned it.
Somewhere in America this morning, a 47-year-old who has dodged the colonoscopy conversation for years signed for a small package. Inside: a kit. No prep, no sedation, no day off work, no clinic. By the time the box ships back, a panel of RNA biomarkers will have told a lab whether anything in their colon deserves a closer look. That box is Geneoscopy's whole argument, made physical.
Geneoscopy is a St. Louis life-sciences company with roughly 61 employees and one very specific obsession: reading the RNA that human cells shed into stool. Its flagship product, ColoSense, is the first FDA-approved multi-target stool RNA test for colorectal cancer screening in adults 45 and up. In June 2026, Medicare agreed to cover it - which is the regulatory equivalent of being handed the keys to the front door.
The company is not, despite the press releases, in the business of selling kits. It is in the business of removing excuses. Colorectal cancer is the second deadliest cancer in the United States, and it is also one of the most preventable - if people actually get screened. They don't. Geneoscopy's entire reason for existing sits in that gap.
A colonoscopy is an excellent test. It is also a test that requires a day of preparation that nobody describes fondly, a procedure that requires sedation, and a logistics chain - time off, a driver home, a calendar that cooperates - that quietly filters out millions of people who simply never get around to it. The medical establishment had a gold standard. What it lacked was attendance.
The founding scene is almost too tidy. During her first clinical rotation at Barnes-Jewish Hospital, medical student Erica Barnell met a 52-year-old patient with Stage IV colorectal cancer. He had never been screened. Not because he didn't care - because he couldn't take the time. The cancer that killed him was the cancer screening was supposed to catch. That patient is the central tension of this entire company: the disease is beatable, and the system keeps losing to inconvenience.
Plenty of companies noticed the same gap. The trick was what to measure. Most reached for DNA - the static mutation record, the thing the rest of the field had standardized on. Geneoscopy reached for something more inconvenient and, it would argue, more honest.
In February 2015, Erica Barnell partnered with her brother Andrew - a Wharton MBA - and recruited computational biologist Yiming Kang. The company was born inside Washington University's entrepreneurship incubator, which is a polite way of saying it started as three people, a thesis, and an unreasonable amount of conviction. The thesis: RNA, not DNA, was the right thing to read.
This was a contrarian call. DNA tells you what could happen - the mutations a cell carries. RNA tells you what is happening right now - which genes are actively switched on. For disease that changes over time, the difference matters. RNA offers a dynamic view of activity rather than a frozen snapshot. The catch, and the reason most people didn't bother, is that RNA is famously fragile and isolating intact human RNA from stool is a genuinely unpleasant technical problem. Geneoscopy's first real invention was simply solving that.
The business half of the sibling pair. Wharton MBA who turned a research thesis into a funded, FDA-cleared, Medicare-covered commercial company.
MD/PhD from WashU (2023), trained at the McDonnell Genome Institute. Met the patient who started it all; led the clinical and regulatory path for ColoSense.
The computational biologist who built the data analysis behind the biomarker panel. The quiet third name on the founding line.
ColoSense pairs Geneoscopy's proprietary method for isolating human RNA from stool with Bio-Rad's Droplet Digital PCR - a technology precise enough to count individual biomarker molecules. The result is a multi-target stool RNA, or "mt-sRNA," panel. No bowel prep. No dietary changes. The test arrives and departs by mail, which is the entire point.
First FDA-approved mt-sRNA colorectal cancer screening test for adults 45+. At-home, no prep. FDA Breakthrough Device.
The proprietary isolation methodology that makes everything else possible - a dynamic read of disease activity, not a static snapshot.
Extending the platform into inflammatory bowel disease and GI companion diagnostics for precision-medicine partnerships.
Conviction is cheap. Sensitivity data is not. In the pivotal CRC-PREVENT trial, ColoSense reported 93% sensitivity for colorectal cancer - meaning it flagged the overwhelming majority of cancers present - and 45% sensitivity for advanced adenomas, the precancerous lesions you most want to catch early. The FDA approved it. The American Cancer Society listed it as a preferred option. CMS agreed to pay for it.
Sensitivity bars are percentages. "Medicare reach" is scaled to fit and represents ~65M eligible beneficiaries, not a percentage. Source: company / trial disclosures.
Partnerships did the rest. Bio-Rad supplied both the Droplet Digital PCR chemistry and the lead check on the Series C - a rare case of a strategic investor literally being inside the product. Labcorp opened the distribution so any provider could order the test. Washington University supplied the science and the founding soil. None of it is glamorous. All of it is load-bearing.
Strip away the regulatory milestones and the mission is almost stubbornly simple: use RNA to prevent, detect, and treat GI disease before it becomes the kind of news no family wants. Colorectal cancer is highly survivable when caught early and brutal when caught late. The difference is screening. The barrier to screening is friction. Geneoscopy's job is to keep deleting friction until the excuse not to screen runs out.
The roadmap points past cancer. The same RNA platform is being aimed at inflammatory bowel disease and at companion diagnostics for precision-medicine partnerships - turning a single clever test into a way of monitoring the gut over time. Whether that pipeline delivers is the open question. The platform, at least, is real.
Return to that 47-year-old signing for the package. A decade ago, their screening options were a procedure they would keep postponing or a DNA-based mail test that read the past. Now there is a third option: a kit that reads what their gut is doing right now, that any provider can order, that Medicare will pay for, and that asks nothing more than the willingness to mail something back.
That is the change Geneoscopy set out to make. Not a cure - a removed excuse. The patient who started this company never got the test that could have saved him. The whole point of the box on the doorstep is that the next person won't have that reason to wait.